Mirati Therapeutics (MRTX) Misses Q4 EPS by 76c

Mirati Therapeutics (NASDAQ: MRTX) reported Q4 EPS of ($3.72), $0.76 worse than the analyst estimate of ($2.96). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $1.41 million.

For earnings history and earnings-related data on Mirati Therapeutics (MRTX) click here.

You May Also Be Interested In

• Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
• Scotiabank Starts Affirm Holdings (AFRM) at Sector Outperform
• BofA downgrades Amrize to underperform, cuts price target on slower growth outlook